Abstract:
Drug particles which are essentially crystalline and have a mean particle size below 2 microns, when dispersed in water, are described. When added to an aqueous medium at 25-95% of the equilibrium solubility of the drug substance, the drug particles show complete dissolution, as characterized by a 95% reduction in turbidity, in less than 5 minutes. Using a controlled precipitation process to prepare such drug particles is also described. Such drug particles exhibit an enhanced dissolution rate and better stability as compared to particles prepared according to processes described in the prior art.
Abstract:
Particles having a plurality of crystalline domains are described. Each crystalline domain is oriented differently than any of the adjacent domains and comprises a drug substance. A plurality of interfacial regions surround the crystalline domains, each interfacial region comprising at least one stabilizer. A process used to prepare the particles of the present invention is also described. The particles of the present invention exhibit relatively fast dissolution times as compared to particles prepared by processes described in the prior art.
Abstract:
A method for producing micron-sized or submicron-sized drugs is disclosed, which comprises preparing a template emulsion comprising water and a templating agent; preparing a drug-containing mixture comprising a drug substance; and combining the template emulsion with the drug-containing mixture to form a template emulsion loaded with drug particles. Drug particles prepared from this process are also disclosed. The resulting drug particles demonstrate faster dissolution rates and enhanced bioavailability as compared to unprocessed drug particles and particles prepared using other processes.
Abstract:
Silane crosslinkable polymer compositions comprise (i) at least one silane crosslinkable polymer, e.g., ethylene-silane copolymer, and (ii) a catalytic amount of at least one polysubstituted aromatic sulfonic acid (PASA). The PASA catalysts are of the formula: HSO 3 Ar-R 1 (R x ) m Where: m is 0 to 3; R 1 is (CH 2 ) n CH 3 , and n is 0 to 3 or greater than 20; Each R x is the same or different than R 1 ; and Ar is an aromatic moiety.
Abstract translation:硅烷交联聚合物组合物包含(i)至少一种硅烷可交联聚合物,例如乙烯 - 硅烷共聚物,和(ii)催化量的至少一种多取代芳族磺酸(PASA)。 PASA催化剂具有下式:HSO 3 Ar-R 1(R x x)m其中:m 是0到3; R 1是(CH 2 CH 2)n CH 3 CH 3,n是0至3或大于20; 每个R x X相同或不同于R 1; 并且Ar是芳族部分。
Abstract:
A method for determining the percent of a solid material dissolved into a liquid medium is disclosed. The method comprises the steps of combining the solid material and the liquid medium; determining the initial solid concentration (i); determining the dynamic solid concentration (d) using a light scattering technique; and calculating the percent dissolved material according to the formula: [(i - d)/i] x 100 . Methods for determining dissolution rate and particle size using turbidity measurements are also disclosed.
Abstract:
This invention is for di-substituted surfactant precursors, surfactants prepared from them, methods of making the di-substituted surfactant precursors and derived surfactants, and to surfactants having the properties of the described surfactants. The di-substituted surfactant precursors and surfactants are derived from admixing water, surfactant, a hydrolysis catalyst, and an initial quantity of a substituted three-membered heterocycle (a substituted l-oxacyclopropane, a substituted 1-thiacyclopropane, or a substituted l-azacyclopropane) and sustaining an emulsion admixture of the di-substituted surfactant precursor, the water, the heterocycle, the surfactant, and the catalyst to yield the di-substituted surfactant precursor. The di-substituted surfactant precursor is further functionalized to achieve desired hydrophilic properties. A new surfactant product is ultimately provided affording a new combination of (in aqueous admixture) critical micelle concentration, viscosity, and clarity properties.
Abstract:
A process for preparing crystalline particles of a drug substance is disclosed, said process comprising recirculating an anti-solvent through a mixing zone, dissolving the drug substance in a solvent to form a solution, adding the solution to the mixing zone to form a article slurry in the anti-solvent, and recirculating at least a portion of the particle slurry back through the mixing zone. Particles produced from the process are also disclosed. The present invention has the ability to be operated in a continuous fashion, resulting in a more efficient process and a more uniform product. The present invention has the additional advantage of having the ability to operate at a relatively low solvent ratio, thereby increasing the drug to excipient ratio.
Abstract:
This invention is cross-linked, polymerized hydrocarbon particles which composition is characterized in that the particles have an average diameter of less than 30 nm, the particles exhibit a volume swell factor of no greater than 3.0; the composition is essentially free of metal ions; the particles have a polydispersity (polystyrene relative Mw/Mn) of less than 3.0, and the particles are characterized by a Mark-Houwink plot having a slope with an absolute value of less than 0.4 for the peak molecular weight range. The invention is also a method of making nanoparticles having a weight average diameter less than 30 nm by emulsion polymerization in the substantial absence of ionic components. Finally, the invention is a method of using such particles as thermally degradable components in making porous films.
Abstract:
This invention is for di-substituted surfactant precursors, surfactants prepared from them, methods of making the di-substituted surfactant precursors and derived surfactants, and to surfactants having the properties of the described surfactants. The di-substituted surfactant precursors and surfactants are derived from admixing water, surfactant, a hydrolysis catalyst, and an initial quantity of a substituted three-membered heterocycle (a substituted l-oxacyclopropane, a substituted 1-thiacyclopropane, or a substituted l-azacyclopropane) and sustaining an emulsion admixture of the di-substituted surfactant precursor, the water, the heterocycle, the surfactant, and the catalyst to yield the di-substituted surfactant precursor. The di-substituted surfactant precursor is further functionalized to achieve desired hydrophilic properties. A new surfactant product is ultimately provided affording a new combination of (in aqueous admixture) critical micelle concentration, viscosity, and clarity properties.